Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new antibody tame lupus flares?

NCT ID NCT07760155

Disease control Sponsor: Shanghai Escugen Biotechnology Co., Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial tests whether an experimental drug called ESG206 can safely reduce disease activity in adults with systemic lupus erythematosus (SLE). Participants will receive either ESG206 or a placebo, and researchers will measure how many achieve a meaningful improvement in lupus symptoms by week 25. The study aims to see if targeting a protein called BAFF-R can help control the immune system's attack on the body.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ESG206, an experimental monoclonal antibody that targets BAFF-R to help control lupus disease activity
What this could lead to
If successful, ESG206 could offer a new treatment option to help control lupus symptoms and reduce disease flares.
What could go wrong
This is an early-stage trial with a small number of participants, so results may not hold up in larger studies. The drug may also cause side effects or fail to show a clear benefit over placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults (≥18 years of age) with a confirmed diagnosis of Systemic Lupus Erythematosus * Evidence of active disease at screening * Willing and able to provide written informed consent Exclusion Criteria: * Have other autoimmune diseases that may interfere with the assessment of SLE * Prior or recent use of prohibited immunomodulatory therapies * Clinically significant infections, malignancies, or uncontrolled medical conditions * Pregnancy or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Systemic lupus erythematosus (SLE) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Systemic lupus erythematosus (SLE)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    20 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Affiliated Hospital of Hebei Engineering University

    Handan, Hebei, China

  • Affiliated Hospital of North Sichuan Medical College

    Nanchong, Sichuan, China

  • Changde First People's Hospital

    Changde, Hunan, China

  • Huzhou Third People's Hospital

    Huzhou, Zhejiang, China

  • Jinhua Municipal Central Hospital

    Jinhua, Zhejiang, China

  • Linfen Central Hospital

    Linfen, Shanxi, China

  • Liupanshui Shougang Shuigang Hospital

    Liupanshui, Guizhou, China

  • Loudi Central Hospital

    Loudi, Hunan, China

  • Mianyang Central Hospital

    Mianyang, Sichuan, China

  • Ningbo Medical Center Lihuili Hospital

    Ningbo, Zhejiang, China

  • Renji Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China

  • Second Affiliated Hospital of Guilin Medical University

    Guilin, Guangxi, China

  • Second Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • Shanghai Tongji Hospital

    Shanghai, Shanghai Municipality, China

  • Shenzhen Third People's Hospital

    Shenzhen, Guangdong, China

  • Xiangya Hospital, Central South University

    Changsha, Hunan, China

  • Xuzhou Central Hospital

    Xuzhou, Jiangsu, China

  • Zhongshan Traditional Chinese Medicine Hospital

    Zhongshan, Guangdong, China

  • Zhuzhou Central Hospital

    Zhuzhou, Hunan, China

  • Zibo Central Hospital

    Zibo, Shandong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.